FDA declines to approve J&J arthritis drug sirukumab |
|
(Reuters) - The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.
|
|
|
|
|
|
|
|
Related Video |
|
|
|
|
|
|
|
|
|
|
A quick-fix on the day's news delivered when you want it. Register Today |
|
|
|
|
|
A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today |
|
|
|
» » MORE NEWSLETTERS |
|
|